MeiraGTx Holdings plcMGTXEarnings & Financial Report
MeiraGTx Holdings plc is a clinical-stage biotechnology firm specializing in the research, development and commercialization of transformative gene therapies. Its core pipeline targets rare ophthalmic conditions, neurodegenerative disorders, and salivary gland diseases, serving patients across global markets with operations in the U.S. and European Union.
Revenue
$3.7M
Gross Profit
N/A
Operating Profit
$-44.8M
Net Profit
$-38.8M
Gross Margin
N/A
Operating Margin
-1213.6%
Net Margin
-1051.1%
YoY Growth
1208.9%
EPS
$-0.48
MeiraGTx Holdings plc Q2 FY2025 Financial Summary
MeiraGTx Holdings plc reported revenue of $3.7M (up 1208.9% YoY) for Q2 FY2025, with a net profit of $-38.8M (up 20.2% YoY) (-1051.1% margin).
Key Financial Metrics
| Total Revenue | $3.7M |
|---|---|
| Net Profit | $-38.8M |
| Gross Margin | N/A |
| Operating Margin | -1213.6% |
| Report Period | Q2 FY2025 |
MeiraGTx Holdings plc Annual Revenue by Year
MeiraGTx Holdings plc annual revenue history includes year-by-year totals (for example, 2024 revenue was $33.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $33.3M |
| 2023 | $14.0M |
| 2022 | $15.9M |
MeiraGTx Holdings plc Quarterly Revenue & Net Profit History
MeiraGTx Holdings plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $410.0K | -96.2% | $-50.5M | -12320.2% |
| Q2 FY2025 | $3.7M | +1208.9% | $-38.8M | -1051.1% |
| Q4 FY2024 | $21.4M | +948.5% | $-39.4M | -184.2% |
| Q3 FY2024 | $10.9M | +113.8% | $-39.3M | -360.5% |
| Q2 FY2024 | $282.0K | -92.0% | $-48.6M | -17241.1% |
| Q1 FY2024 | $697.0K | -79.1% | $-20.4M | -2932.9% |
| Q4 FY2023 | $2.0M | +138.6% | N/A | N/A |
| Q3 FY2023 | $5.1M | +6.0% | $-44.3M | -868.1% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $2.0M | $697000 | $282000 | $10.9M | $21.4M | $3.7M | $410000 |
| YoY Growth | 6.0% | 138.6% | -79.1% | -92.0% | 113.8% | 948.5% | 1208.9% | -96.2% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $267.2M | $326.7M | $309.2M | $266.7M | $299.5M | $269.8M | $198.7M | $189.5M |
| Liabilities | $175.3M | $188.6M | $187.5M | $186.6M | $203.8M | $201.9M | $195.8M | $230.0M |
| Equity | $91.9M | $138.2M | $121.7M | $80.0M | $95.7M | $67.8M | $3.0M | $-40.6M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-24.4M | $-105.4M | $-36.7M | $-19.5M | $-25.0M | $-23.3M | $-43.9M | $-12.2M |